Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team
Press release

Redeye: Sprint Bioscience Q4 - Confident expansion

Sprint Bioscience

Sprint Bioscience delivered Q4 sales within the recent range at SEK 16.3m (SEK 14.8m in Q3), mostly related to the Day One Biopharmaceuticals partner and the VADA project. The cash balance was SEK 25.1m in Q4 (SEK 31.7m in Q3 and 36m in Q2 2024). Sprint Bioscience continues to market and engage in conversations with potential partners for VP34, TREX1 (DISA), NIMA and MASH programs. During the quarter, Sprint Bioscience is also evaluating the PETRA01 program.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments


Sprint Bioscience Q4 - Confident expansion

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.